## Integrin a6 targeted positron emission tomography imaging of colorectal cancer

Yi-Tai Xiao<sup>1#</sup>, Chao Zhou<sup>2#</sup>, Jia-Cong Ye<sup>3#</sup>, Xiao-Chun Yang<sup>2</sup>, Zhi-Jian Li<sup>2</sup>, Xiao-Bin Zheng<sup>2</sup>, Yan Mei<sup>3</sup>, Xin-Ling

Li<sup>2</sup>, Wei-Guang Zhang<sup>2</sup>, Wei Fan<sup>2</sup>, Mu-Sheng Zeng<sup>3</sup>, Jian-Jun Li<sup>1\*</sup>, Guo-Kai Feng<sup>3\*</sup>

Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

<sup>1</sup>Department of Endoscopy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for

<sup>2</sup>Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation

Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

<sup>3</sup>Department of Experiment, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.



Figure S1. The stability *in vitro* of <sup>18</sup>F-RWY analyzed by HPLC. <sup>18</sup>F-RWY exhibits a unique radioactive peak consistent with high purity and stability.



**Figure S2. 3D model PET/CT image with <sup>18</sup>F-RWY in a chemically induced CRC mouse.** Maximal intensity projections (MIP) showed accumulation of radioactivity in tumor, kidneys, and urinary bladder (arrows).



**Figure S3. 3D model PET/CT image with <sup>18</sup>F-RWY in a genetically engineered CRC mouse.** Maximal intensity projections (MIP) showed accumulation of radioactivity in tumor, kidneys, and urinary bladder (arrows).



**Figure S4. PET/CT imaging with** <sup>18</sup>**F-FDG in a genetically engineered CRC mouse.** <sup>18</sup>F-FDG mainly accumulated in kidneys, urinary bladder, and some non-specific sites, such as the heart, the brain, and the subcutaneous adipose tissue.